Abstract
Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 1451-1462 |
Number of pages | 12 |
Journal | Leukemia and Lymphoma |
Volume | 55 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2014 |
Externally published | Yes |
Keywords
- Drug resistance
- Myeloid leukemias and dysplasias
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research